<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-29479" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Stent Thrombosis</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Modi</surname>
            <given-names>Kalgi</given-names>
          </name>
          <aff>Louisiana State University HSC</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Soos</surname>
            <given-names>Michael P.</given-names>
          </name>
          <aff>McLaren Greater Lansing</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Mahajan</surname>
            <given-names>Kunal</given-names>
          </name>
          <aff>Holy Heart Advanced Cardiac Care Centre</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Kalgi Modi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Michael Soos declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Kunal Mahajan declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>25</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-29479.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Stent thrombosis, also known as abrupt vessel closure and acute stent thrombosis, is one of the fatal complications of percutaneous coronary intervention. A high clinical suspicion is needed for the evaluation of this condition, and measures are needed to promptly restore patency of the thrombosed vessels. This activity reviews the evaluation of stent thrombosis and highlights the role of the interprofessional team in improving care for those with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Explain the causes of stent thrombosis.</p></list-item><list-item><p>Describe the pathophysiology of stent thrombosis.</p></list-item><list-item><p>Summarize the treatment of stent thrombosis.</p></list-item><list-item><p>Review the importance of improving care coordination among the interprofessional team in having a high clinical suspicion for this condition in patients who present with angina and a recent history of coronary stenting for prompt diagnosis and better outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=29479&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=29479">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-29479.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Stent thrombosis is defined as a thrombotic occlusion of a coronary stent. Stent thrombosis is a major complication associated with stent placement in percutaneous coronary intervention (PCI). Stent thrombosis has been associated with high rates of morbidity and mortality, often leading to events of cardiac death or nonfatal myocardial infarction (MI).<xref ref-type="bibr" rid="article-29479.r1">[1]</xref><xref ref-type="bibr" rid="article-29479.r2">[2]</xref><xref ref-type="bibr" rid="article-29479.r3">[3]</xref>&#x000a0;Often compared to in-stent restenosis, which leads to anginal type symptoms, stent thrombosis is typically an acute process resulting in acute coronary syndrome (ACS). Various risk factors have been associated with stent thrombosis, including a history of diabetes mellitus (DM), ACS, and reduced left ventricular ejection fraction (LVEF). In 2008, the Academic Research Consortium (ARC) guidelines were published regarding the classifications of stent thrombosis.<xref ref-type="bibr" rid="article-29479.r4">[4]</xref> Classifications were divided based on the type of underlying stent, clinical scenario, and timing after initial stent placement.</p>
        <list list-type="bullet">
          <list-item>
            <p>Based on the&#x000a0;underlying stent, stent thrombosis should be divided into categories of a bare-metal stent (BMS), a first-generation drug-eluting stent (DES), and second-generation DES.</p>
          </list-item>
        </list>
        <p>In terms of timing, there are a variety of categories for stent thrombosis. Timing may be divided between acute, subacute, early, late, and very late. Early stent thrombosis is divided between acute or subacute:</p>
        <list list-type="bullet">
          <list-item>
            <p>Acute thrombosis occurs within 24 hours of initial placement.</p>
          </list-item>
          <list-item>
            <p>Subacute thrombosis occurs between 24 hours to one month of initial placement.</p>
          </list-item>
        </list>
        <p>When classified as early, late, or very late:</p>
        <list list-type="bullet">
          <list-item>
            <p>Early stent thrombosis occurs within one month of initial placement.</p>
          </list-item>
          <list-item>
            <p>Late stent thrombosis occurs between 1 and 12 months of initial placement.</p>
          </list-item>
          <list-item>
            <p>Very late stent thrombosis occurs after 12 months of initial placement.<xref ref-type="bibr" rid="article-29479.r5">[5]</xref></p>
          </list-item>
        </list>
        <p>Based on the clinical scenario, stent thrombosis may be symptomatic or clinically silent. As noted above, due to the nature of acute thrombotic occlusion stent thrombosis typically results in ACS. Stent thrombus should be classified based on how the diagnosis is confirmed. These classifications include definite, probable, and possible stent thrombosis.&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Silent occlusion<bold>- </bold>Incidental stent occlusion on angiography in the absence of clinical signs or symptoms is not considered stent thrombosis.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Possible stent thrombosis
<list list-type="bullet"><list-item><p>Consider with unexplained death 30 days or later after stent placement.</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Probable stent thrombosis
<list list-type="bullet"><list-item><p>Any unexplained death within 30 days of stent placement.</p></list-item><list-item><p>Consider if there is active ischemia on electrocardiogram (EKG) or stress in the distribution of prior stent and absence of significant coronary lesion on angiography.</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Definite stent thrombosis
<list list-type="bullet"><list-item><p>Requires confirmation of stent thrombosis on angiography
<list list-type="bullet"><list-item><p>Within the existing stent</p></list-item><list-item><p>Within 5 mm proximal or distal to the stent</p></list-item></list>
</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>
<list list-type="bullet"><list-item><p>Plus one of the following within 48 hours
<list list-type="bullet"><list-item><p>Acute onset of ischemic symptoms at rest</p></list-item><list-item><p>New ischemic changes on ECG</p></list-item><list-item><p>A typical rise in cardiac biomarkers</p></list-item><list-item><p>Thrombus on autopsy or retrieved with thrombectomy</p></list-item></list>
</p></list-item></list>
</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-29479.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Large randomized trials and registry have identified patient/lesion, procedural, or stent factors related to stent thrombosis.<xref ref-type="bibr" rid="article-29479.r6">[6]</xref><xref ref-type="bibr" rid="article-29479.r7">[7]</xref>&#x000a0;Champion-phoenix trial identified Non-ST-elevation myocardial infarction (NSTEMI) and&#x000a0;ST-elevation myocardial infarction&#x000a0;(STEMI) at presentation, angiographic thrombus burden, and total stent length as independent predictors of acute stent thrombosis.<xref ref-type="bibr" rid="article-29479.r8">[8]</xref>&#x000a0;An acuity trial revealed diabetes mellitus, renal insufficiency, Duke jeopardy score, final stent minimal luminal diameter, preprocedural thienopyridine administration, baseline hemoglobin, and extent of coronary artery disease as independent factors associated with early stent thrombosis. In an intravascular ultrasound (IVUS) substudy of the Horizon AMI (acute myocardial infarction) trial, the small cross-sectional area of less than 5 mm, malposition of stent struts, plaque prolapse or protrusion, edge dissection, and residual stenosis played significant roles in predicting early stent thrombosis.<xref ref-type="bibr" rid="article-29479.r9">[9]</xref> Also, bifurcation stenting contributed to stent thrombosis. The Triton TIMI 38 trial showed that patients with STEMI are at higher risk of stent thrombosis regardless of stent type and that more potent antiplatelet therapy such as prasugrel reduced that risk by 50%.<xref ref-type="bibr" rid="article-29479.r10">[10]</xref></p>
      </sec>
      <sec id="article-29479.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Stent thrombosis has been recognized from the early era of stent deployment, with an incidence as high as 16% in earlier studies. Fifteen to 30% of the patients with stent thrombosis die within 30 days of the event.<xref ref-type="bibr" rid="article-29479.r11">[11]</xref> Acetylsalicylic acid (ASA), dipyridamole, coumadin, and dextran were tried in the early stenting era to prevent the event. With the current practice of dual antiplatelet therapy and high-pressure inflation has significantly decreased incidence to 0.7% in one&#x000a0;year and about 0.2% to 0.6% the year after that. The rate is lower for elective percutaneous intervention (PCI) (0.3% to 0.5%) but as high as 3.4% for acute coronary syndrome. There has been overall no significant difference between the rate of stent thrombosis between bare-metal stents and eluting drug stents. Only the timing of the event varies. The bare-metal stent tends to have an early event with a peak of around 30 days compared to drug-eluting stents around three months to even later depending on the drug-coated.<xref ref-type="bibr" rid="article-29479.r12">[12]</xref><xref ref-type="bibr" rid="article-29479.r13">[13]</xref></p>
      </sec>
      <sec id="article-29479.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Virchow&#x02019;s triad explains the major factors that lead to stent thrombosis.<xref ref-type="bibr" rid="article-29479.r14">[14]</xref> First, stasis and turbulence caused by an under-expanded stent, a stent in a small vessel, or a long lesion. Second, injury or endothelial disruption caused by edge dissection or delayed healing with eluting drug stents. Finally, hypercoagulability caused by congenital or acquired or nonresponder.<xref ref-type="bibr" rid="article-29479.r15">[15]</xref></p>
      </sec>
      <sec id="article-29479.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>A thorough history, medication compliance review, laboratory testing for P2Y12 resistance, a 12 lead EKG, echocardiogram looking for a new wall motion abnormality, and laboratory testing of cardiac enzymes is recommended for initial evaluation of a patient with recent percutaneous coronary intervention presenting with angina.<xref ref-type="bibr" rid="article-29479.r16">[16]</xref> Universally, 60% of the patients with stent thrombosis present with STEMI and 40% with NSTEMI or unstable angina. Patients with STEMI, in the context of stent thrombosis, have greater rates of in-hospital mortality (17.4%). Patients with early stent thrombosis are more likely to develop cardiogenic shock than to&#x000a0;develop late or very late stent thrombosis. It is very unlikely that a patient with nonacute coronary syndrome presentation would have evidence of stent thrombosis on subsequent coronary angiograms performed.</p>
      </sec>
      <sec id="article-29479.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>High clinical suspicion is the most important evaluation for a patient presenting with angina and a recent history of coronary stenting. The patient is usually evaluated with history, physical examination, EKG, echocardiogram, and cardiac enzymes. Almost all patients with&#x000a0;STEMI undergo urgent coronary angiography.<xref ref-type="bibr" rid="article-29479.r11">[11]</xref></p>
      </sec>
      <sec id="article-29479.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>During angiography, a prompt aspiration thrombectomy or angioplasty should be performed to restore the patency of the thrombosed vessel. Compliance and drug resistance should be evaluated. More potent antiplatelet therapy should be considered, for example, prasugrel or ticagrelor.<xref ref-type="bibr" rid="article-29479.r17">[17]</xref><xref ref-type="bibr" rid="article-29479.r18">[18]</xref><xref ref-type="bibr" rid="article-29479.r19">[19]</xref>&#x000a0;The current recommendation is to continue the dual antiplatelet drug therapy for one year after drug-eluting stent placement and at least one month following bare-metal stent. The stent should be assessed with either&#x000a0;intravascular ultrasound (IVUS) or optical coherence tomography (OCT) to determine stent apposition, expansion, and the presence of edge dissections. Optimization of stent deployment with appropriate postulation and treatment of edge dissections with additional stents are imperative to prevent repeat stent thrombosis. Additional stent implantation should be avoided if possible because each millimeter of the stent increases the probability of stent thrombosis.</p>
      </sec>
      <sec id="article-29479.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>One differential diagnosis includes:</p>
        <list list-type="bullet">
          <list-item>
            <p>in-stent restenosis, which leads to anginal type symptoms.</p>
          </list-item>
        </list>
        <p>Stent thrombosis is typically a more acute process resulting in acute coronary syndrome (ACS). Additionally, episodes of ACS within native vessels should be excluded.</p>
      </sec>
      <sec id="article-29479.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Stent thrombosis has been associated with high rates of morbidity and mortality, often leading to events of cardiac death or nonfatal myocardial infarction (MI).&#x000a0;When compared to in-stent restenosis, which leads to anginal type symptoms, stent thrombosis is typically an acute process resulting in acute coronary syndrome (ACS). Prognosis improves greatly with early identification and intervention. High clinical suspicion and detailed history taking are crucial for an accurate diagnosis.<xref ref-type="bibr" rid="article-29479.r15">[15]</xref></p>
      </sec>
      <sec id="article-29479.s11" sec-type="Complications">
        <title>Complications</title>
        <p>Stent thrombosis is a major complication associated with stent placement in PCI. Complications associated with untreated stent thrombosis include death, myocardial infarction, and cardiogenic shock. Complications related to the treatment of stent thrombosis are similar to that of PCI. These include but are not limited to bruising, hematoma, pseudoaneurysm, retroperitoneal hemorrhage, arrhythmia, contrast-induced nephropathy, thrombus formation, infection, ischemic stroke, and myocardial infarction.<xref ref-type="bibr" rid="article-29479.r20">[20]</xref></p>
      </sec>
      <sec id="article-29479.s12" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patients should be educated following PCI with DES placement of the risks associated with stent thrombosis in the postoperative period.<xref ref-type="bibr" rid="article-29479.r21">[21]</xref> Additionally, patients should be instructed to present to the emergency department for further evaluation if typical anginal or acute coronary syndrome symptoms should develop.</p>
      </sec>
      <sec id="article-29479.s13" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>When patients with stents present with chest pain to the primary care provider, internist, and nurse practitioner, one should always consider stent thrombosis. These patients should be immediately referred to the cardiologist for further investigation and treatment. Stent thrombosis, when it occurs acutely, can be fatal if not treated right away. The triage nurse should be aware of this condition and immediately admit the patient and consult with the emergency department provider. Careful monitoring by the nursing staff is required with frequent reports to the providers. Due to the complexity of treatment, a specially trained cardiac pharmacist should assist with medication selection, dosing, and monitoring working with the clinical team. The prognosis depends on many factors, including patient age, duration of thrombosis, number of stents involved, and response to medical treatment. In some cases, an urgent coronary bypass is required.<xref ref-type="bibr" rid="article-29479.r22">[22]</xref><xref ref-type="bibr" rid="article-29479.r23">[23]</xref><xref ref-type="bibr" rid="article-29479.r24">[24]</xref>&#x000a0;(Level 2)</p>
      </sec>
      <sec id="article-29479.s14">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=29479&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=29479">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/heart-health/stent-thrombosis/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=29479">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/29479/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=29479">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-29479.s15">
        <fig id="article-29479.image.f1" position="float" orientation="portrait">
          <caption>
            <p>IVUS-in stent thrombosis Image courtesy S Bhimji MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="IVUS" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-29479.s16">
        <title>References</title>
        <ref id="article-29479.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Longobardo</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Mattesini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Valente</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Di Mario</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>OCT-guided Percutaneous Coronary Intervention in Bifurcation Lesions.</article-title>
            <source>Interv Cardiol</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>14</volume>
            <issue>1</issue>
            <fpage>5</fpage>
            <page-range>5-9</page-range>
            <pub-id pub-id-type="pmid">30858885</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29479.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Piranavan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kaur</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Marmoush</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Burton</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hannan</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Ticagrelor-induced Angioedema After Percutaneous Coronary Intervention in a Patient with a History of Ischemic Stroke and Low Response to Clopidogrel: A Rare Dilemma.</article-title>
            <source>Cureus</source>
            <year>2018</year>
            <month>Dec</month>
            <day>11</day>
            <volume>10</volume>
            <issue>12</issue>
            <fpage>e3720</fpage>
            <pub-id pub-id-type="pmid">30891370</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29479.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>SN</given-names>
              </name>
              <name>
                <surname>Moon</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Moon</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Yoo</surname>
                <given-names>KD</given-names>
              </name>
            </person-group>
            <article-title>The Glasgow prognostic score as a significant predictor of clinical outcomes in patients with acute coronary syndrome.</article-title>
            <source>J Cardiol</source>
            <year>2019</year>
            <month>Aug</month>
            <volume>74</volume>
            <issue>2</issue>
            <fpage>130</fpage>
            <page-range>130-135</page-range>
            <pub-id pub-id-type="pmid">30878352</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29479.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cutlip</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Nakazawa</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Krucoff</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Vorpahl</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mehran</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Finn</surname>
                <given-names>AV</given-names>
              </name>
              <name>
                <surname>Vranckx</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kimmelstiel</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Berger</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Petersen</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Palabrica</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Virmani</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Autopsy validation study of the academic research consortium stent thrombosis definition.</article-title>
            <source>JACC Cardiovasc Interv</source>
            <year>2011</year>
            <month>May</month>
            <volume>4</volume>
            <issue>5</issue>
            <fpage>554</fpage>
            <page-range>554-9</page-range>
            <pub-id pub-id-type="pmid">21596329</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29479.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Che</surname>
                <given-names>QQ</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Liang</surname>
                <given-names>YB</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Lyu</surname>
                <given-names>QW</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>QY</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bai</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>[Meta-analysis on safety and efficacy of dual antiplatelet therapy combining with proton pump inhibitors for patients after percutaneous coronary intervention].</article-title>
            <source>Zhonghua Xin Xue Guan Bing Za Zhi</source>
            <year>2019</year>
            <month>Feb</month>
            <day>24</day>
            <volume>47</volume>
            <issue>2</issue>
            <fpage>129</fpage>
            <page-range>129-140</page-range>
            <pub-id pub-id-type="pmid">30818941</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29479.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lv</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>ZL</given-names>
              </name>
            </person-group>
            <article-title>De-escalation versus standard dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis.</article-title>
            <source>Platelets</source>
            <year>2020</year>
            <volume>31</volume>
            <issue>1</issue>
            <fpage>15</fpage>
            <page-range>15-25</page-range>
            <pub-id pub-id-type="pmid">30759033</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29479.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Xie</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Xiang</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Gong</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cui</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Predictive Value of Methods Measuring Platelet Activation for Ischemic Events in Patients Receiving Clopidogrel: A Systematic Review and Meta-analysis.</article-title>
            <source>Curr Pharm Des</source>
            <year>2018</year>
            <volume>24</volume>
            <issue>44</issue>
            <fpage>5313</fpage>
            <page-range>5313-5333</page-range>
            <pub-id pub-id-type="pmid">30727868</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29479.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>G&#x000e9;n&#x000e9;reux</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Stone</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>Harrington</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Gibson</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Steg</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Brener</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Angiolillo</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Price</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Prats</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>LaSalle</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Todd</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Skerjanec</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hamm</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Mahaffey</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>HD</given-names>
              </name>
              <name>
                <surname>Bhatt</surname>
                <given-names>DL</given-names>
              </name>
              <collab>CHAMPION PHOENIX Investigators</collab>
            </person-group>
            <article-title>Impact of intraprocedural stent thrombosis during percutaneous coronary intervention: insights from the CHAMPION PHOENIX Trial (Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention).</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2014</year>
            <month>Feb</month>
            <day>25</day>
            <volume>63</volume>
            <issue>7</issue>
            <fpage>619</fpage>
            <page-range>619-629</page-range>
            <pub-id pub-id-type="pmid">24184169</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29479.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dangas</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>Claessen</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>Mehran</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Stone</surname>
                <given-names>GW</given-names>
              </name>
            </person-group>
            <article-title>Stent thrombosis after primary angioplasty for STEMI in relation to non-adherence to dual antiplatelet therapy over time: results of the HORIZONS-AMI trial.</article-title>
            <source>EuroIntervention</source>
            <year>2013</year>
            <month>Jan</month>
            <day>22</day>
            <volume>8</volume>
            <issue>9</issue>
            <fpage>1033</fpage>
            <page-range>1033-9</page-range>
            <pub-id pub-id-type="pmid">23339809</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29479.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Husted</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Boersma</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Case Study: Ticagrelor in PLATO and Prasugrel in TRITON-TIMI 38 and TRILOGY-ACS Trials in Patients With Acute Coronary Syndromes.</article-title>
            <source>Am J Ther</source>
            <year>2016</year>
            <season>Nov/Dec</season>
            <volume>23</volume>
            <issue>6</issue>
            <fpage>e1876</fpage>
            <page-range>e1876-e1889</page-range>
            <pub-id pub-id-type="pmid">25830867</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29479.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Noaman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>O'Brien</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Andrianopoulos</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Brennan</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Dinh</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Reid</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Stub</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Biswas</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Freeman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ajani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Yip</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Duffy</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Oqueli</surname>
                <given-names>E</given-names>
              </name>
              <collab>Melbourne Interventional Group Investigators</collab>
            </person-group>
            <article-title>Clinical outcomes following ST-elevation myocardial infarction secondary to stent thrombosis treated by percutaneous coronary intervention.</article-title>
            <source>Catheter Cardiovasc Interv</source>
            <year>2020</year>
            <month>Oct</month>
            <day>01</day>
            <volume>96</volume>
            <issue>4</issue>
            <fpage>E406</fpage>
            <page-range>E406-E415</page-range>
            <pub-id pub-id-type="pmid">32087042</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29479.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Her</surname>
                <given-names>AY</given-names>
              </name>
              <name>
                <surname>Jeong</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>BK</given-names>
              </name>
              <name>
                <surname>Hong</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Ahn</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Ko</surname>
                <given-names>YG</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hong</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Jang</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>A comparison of the impact of current smoking on 2-year major clinical outcomes of first- and second-generation drug-eluting stents in acute myocardial infarction: Data from the Korea Acute Myocardial Infarction Registry.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>98</volume>
            <issue>10</issue>
            <fpage>e14797</fpage>
            <pub-id pub-id-type="pmid">30855497</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29479.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhao</surname>
                <given-names>XY</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>JX</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>XF</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gao</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Gao</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Qiao</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>YJ</given-names>
              </name>
              <name>
                <surname>Gao</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Yuan</surname>
                <given-names>JQ</given-names>
              </name>
            </person-group>
            <article-title>Validation of Predictive Value of Patterns of Nonadherence to Antiplatelet Regimen in Stented Patients Thrombotic Risk Score in Chinese Population Undergoing Percutaneous Coronary Intervention: A Prospective Observational Study.</article-title>
            <source>Chin Med J (Engl)</source>
            <year>2018</year>
            <month>Nov</month>
            <day>20</day>
            <volume>131</volume>
            <issue>22</issue>
            <fpage>2699</fpage>
            <page-range>2699-2704</page-range>
            <pub-id pub-id-type="pmid">30425196</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29479.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yahagi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kolodgie</surname>
                <given-names>FD</given-names>
              </name>
              <name>
                <surname>Otsuka</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Finn</surname>
                <given-names>AV</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Joner</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Virmani</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Pathophysiology of native coronary, vein graft, and in-stent atherosclerosis.</article-title>
            <source>Nat Rev Cardiol</source>
            <year>2016</year>
            <month>Feb</month>
            <volume>13</volume>
            <issue>2</issue>
            <fpage>79</fpage>
            <page-range>79-98</page-range>
            <pub-id pub-id-type="pmid">26503410</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29479.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ge</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Acute Coronary Stent Thrombosis in Modern Era: Etiology, Treatment, and Prognosis.</article-title>
            <source>Cardiology</source>
            <year>2017</year>
            <volume>137</volume>
            <issue>4</issue>
            <fpage>246</fpage>
            <page-range>246-255</page-range>
            <pub-id pub-id-type="pmid">28472800</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29479.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Godschalk</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Willemsen</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Zwart</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bergmeijer</surname>
                <given-names>TO</given-names>
              </name>
              <name>
                <surname>Janssen</surname>
                <given-names>PWA</given-names>
              </name>
              <name>
                <surname>Kelder</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Hackeng</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Ten Berg</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Effect of Tailored Antiplatelet Therapy to Reduce Recurrent Stent Thrombosis and Cardiac Death After a First Episode of Stent Thrombosis.</article-title>
            <source>Am J Cardiol</source>
            <year>2017</year>
            <month>May</month>
            <day>15</day>
            <volume>119</volume>
            <issue>10</issue>
            <fpage>1500</fpage>
            <page-range>1500-1506</page-range>
            <pub-id pub-id-type="pmid">28318511</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29479.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Redfors</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Dworeck</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Haraldsson</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Anger&#x000e5;s</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Odenstedt</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ioanes</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Petursson</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>V&#x000f6;lz</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Albertsson</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>R&#x000e5;munddal</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Persson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Koul</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Erlinge</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Omerovic</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Pretreatment with P2Y12 receptor antagonists in ST-elevation myocardial infarction: a report from the Swedish Coronary Angiography and Angioplasty Registry.</article-title>
            <source>Eur Heart J</source>
            <year>2019</year>
            <month>Apr</month>
            <day>14</day>
            <volume>40</volume>
            <issue>15</issue>
            <fpage>1202</fpage>
            <page-range>1202-1210</page-range>
            <pub-id pub-id-type="pmid">30851037</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29479.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guy</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schnell</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Chevalier</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Verdier</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Corone</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Doutreleau</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kervio</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Carr&#x000e9;</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Incidence of major adverse cardiac events in men wishing to continue competitive sport following percutaneous coronary intervention.</article-title>
            <source>Arch Cardiovasc Dis</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>112</volume>
            <issue>4</issue>
            <fpage>226</fpage>
            <page-range>226-233</page-range>
            <pub-id pub-id-type="pmid">30612894</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29479.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Capodanno</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Alfonso</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Levine</surname>
                <given-names>GN</given-names>
              </name>
              <name>
                <surname>Valgimigli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Angiolillo</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>ACC/AHA Versus ESC Guidelines on Dual&#x000a0;Antiplatelet Therapy: JACC Guideline Comparison.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2018</year>
            <month>Dec</month>
            <day>11</day>
            <volume>72</volume>
            <issue>23 Pt A</issue>
            <fpage>2915</fpage>
            <page-range>2915-2931</page-range>
            <pub-id pub-id-type="pmid">30522654</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29479.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Torrado</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Buckley</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Dur&#x000e1;n</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Trujillo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Toldo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Valle Raleigh</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Abbate</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Biondi-Zoccai</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Guzm&#x000e1;n</surname>
                <given-names>LA</given-names>
              </name>
            </person-group>
            <article-title>Restenosis, Stent Thrombosis, and Bleeding Complications: Navigating Between Scylla&#x000a0;and&#x000a0;Charybdis.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2018</year>
            <month>Apr</month>
            <day>17</day>
            <volume>71</volume>
            <issue>15</issue>
            <fpage>1676</fpage>
            <page-range>1676-1695</page-range>
            <pub-id pub-id-type="pmid">29650125</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29479.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rokoszak</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Syed</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Salata</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Greco</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>de Mestral</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hussain</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Aljabri</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Verma</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Al-Omran</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>A systematic review and meta-analysis of plain versus drug-eluting balloon angioplasty in the treatment of juxta-anastomotic hemodialysis arteriovenous fistula stenosis.</article-title>
            <source>J Vasc Surg</source>
            <year>2020</year>
            <month>Mar</month>
            <volume>71</volume>
            <issue>3</issue>
            <fpage>1046</fpage>
            <page-range>1046-1054.e1</page-range>
            <pub-id pub-id-type="pmid">32089200</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29479.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abdelaziz</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>Abuomara</surname>
                <given-names>HZ</given-names>
              </name>
              <name>
                <surname>Ali</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Eichhofer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Saad</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Routine use of optical coherence tomography in bioresorbable vascular scaffold implantation: insights on technique optimization and long-term outcomes.</article-title>
            <source>Coron Artery Dis</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>30</volume>
            <issue>4</issue>
            <fpage>263</fpage>
            <page-range>263-269</page-range>
            <pub-id pub-id-type="pmid">30883433</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29479.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Agarwal</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mahmoud</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Mojadidi</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Golwala</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Elgendy</surname>
                <given-names>IY</given-names>
              </name>
            </person-group>
            <article-title>Dual versus triple antithrombotic therapy in patients undergoing percutaneous coronary intervention-meta-analysis and meta-regression.</article-title>
            <source>Cardiovasc Revasc Med</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>20</volume>
            <issue>12</issue>
            <fpage>1134</fpage>
            <page-range>1134-1139</page-range>
            <pub-id pub-id-type="pmid">30862490</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29479.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hommels</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Hermanides</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Rasoul</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Berta</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>IJsselmuiden</surname>
                <given-names>AJJ</given-names>
              </name>
              <name>
                <surname>Jessurun</surname>
                <given-names>GAJ</given-names>
              </name>
              <name>
                <surname>Benit</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Pereira</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>De Luca</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kedhi</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Everolimus-eluting bioresorbable scaffolds for treatment of coronary artery disease in patients with diabetes mellitus: the midterm follow-up of the prospective ABSORB DM Benelux study.</article-title>
            <source>Cardiovasc Diabetol</source>
            <year>2019</year>
            <month>Mar</month>
            <day>09</day>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>25</fpage>
            <pub-id pub-id-type="pmid">30851731</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
